Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib

Table 1 Baseline patient characteristics and comparison of disease control rate between different baseline characteristics

Characteristic	Overall (n = 95)	CR + PR + SD (n = 60)	DCR (63.2)	P value2
Sex				1.000
Male	88	56	63.6
Female	7	4	57.1
Age (yr)1	48.2 ± 11			0.390
< 60	80	52	65
≥ 60	15	8	53.3
α-fetoprotein level (ng/mL)				0.822
< 400	42	26	61.9
≥ 400	53	34	64.2
ECOG performance				0.752
0	66	41	62.1
1	29	19	65.5
Hepatitis B				0.745
No	5	4	80
Yes	90	56	62.2
Previous TACE				0.019
No	58	42	72.4
Yes	37	18	48.6
Ascites				0.719
Absent	52	32	61.5
Present	43	28	65.1
Child-Pugh classification				0.373
A	80	49	61.3
B	15	11	73.3
PVTT				0.010
Absent	49	37	75.5
Present	46	23	50
Extrahepatic metastasis				0.103
No	69	47	68.1
Yes	26	13	50
Number of tumor				0.952
1	16	10	62.5
≥ 2	79	50	63.3
Maximum tumor diameter (cm)1	9.5 ± 4.5			1.000
≤ 3	9	6	66.7
> 3	86	54	62.8

¹Data are mean ± SD;

²Determined by χ² test. CR: Complete response; PR: Partial response; SD: Stable disease; DCR: Disease control rate; ECOG: Eastern Cooperative Oncology Group; TACE: Transarterial chemoembolization; PVTT: Portal vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer.